Global Angina Pectoris Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2012 To 2022

Description: Angina pectoris treatment market was esteemed at USD 7,962.8 Mn in 2015, and is required to achieve USD 12,589.6 Mn by 2022, extending at a CAGR of 5.2% from 2016 to 2022.

Market Insights:

As indicated by American College of Cardiology, Chronic angina influences more than seven million North Americans and regardless of ideal pharmacological and interventional treatments, 32% of these patients stay symptomatic from coronary course sickness (CAD). The market specialists recommend that, different methodologies have included new pharmacologic antianginal operators, interventional methodologies, and restorative angiogenesis for treatment of angina pectoris. The beta adrenergic blockers are the principal line drugs and the biggest medication class portion in angina pectoris treatment market. The central point helping development of beta adrenergic blockers are the effectiveness, quick onset of activity, openness to patients and high patient consistence. A couple drugs in stage III of clinical trials are seen as the most potential particles in the angina pectoris treatment. These potential atoms are, for example, Dantonic/T89 (Tasly Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.), and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the biggest market internationally because of variables, for example, Rising predominance of angina pectoris, stoutness in youthful populace, stationary way of life, and rising mindfulness identified with early analysis of angina pectoris.

Pipeline Analysis:

The stage III medications incorporated into the pipeline investigation are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co., Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). Dantonic/T89 is seen as the most potential medication atom in angina pectoris treatment sooner rather than later. As indicated by Tasly Pharmaceuticals, Inc. the study fruition of stage III trial for Dantonic would be by December 2016. As per U.S. National Institutes of Health, Dantonic (T89) is a plant medication that contains concentrates of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a case structure. The medication is as of now affirmed in 26 nations outside the USA for the treatment and aversion of interminable stable angina pectoris and other cardiovascular infection related conditions. This vital confirmative Phase III clinical trial is to affirm the viability and wellbeing of the medication at 150mg and 225mg measurements in the aversion and treatment of angina pectoris in patients with Chronic Stable Angina. In this way, as per its uncommon results anticipated in stage II recommend that Dantonic would be the most potential pipeline drug for angina pectoris treatment.

Key Market Movements:

- Rising commonness of angina pectoris because of stationary way of life and corpulence in youthful era
- High interest for target particular and customized drugs for angina pectoris treatment
- In creating nations from Asia Pacific and Latin America the mindfulness identified with cardiovascular illnesses in expanding

Reasons to Purchase:

- Explore global Angina pectoris treatment Market growth rate, market size and projection to 2022
- Key market constraints and drivers of global Angina pectoris treatment Market
- Challenges to market growth of global Angina pectoris treatment Market industry
- Major prospects in the Angina pectoris treatment Market
- In-Depth regional evaluations by application (Europe, North America APAC and Rest of the World) of global Angina pectoris treatment Market business
- Competitive background, with Angina pectoris treatment Market firm market share and detailed overviews/
summaries of major industry/business competitors

Contents:
Chapter 1 Preface
  1.1 Report Description
  1.1.1 Study Purpose
  1.1.2 Target Audience
  1.1.3 USP and Key Offerings
  1.2 Research Methodology

Chapter 2 Executive Summary
  2.1 Global Angina Pectoris Treatment Market Portrait
  2.2 Global Angina Pectoris Treatment Market, by Drug Class, 2015 (USD Mn)
  2.3 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Angina Pectoris Treatment Market: Market Dynamics and Outlook
  3.1 Angina Pectoris Treatment Market Overview
  3.2 Market Inclination Insights
  3.3 Market Dynamics
  3.3.1 Drivers
  3.3.2 Challenges
  3.3.3 Opportunities
  3.4 Attractive Investment Proposition
  3.5 Competitive Analysis
  3.5.1 Market Share Analysis: Global Angina Pectoris Treatment Market, 2015 (Value %)

Chapter 4 Global Angina Pectoris Treatment Market, By Drug Class
  4.1 Preface
  4.2 Antiplatelet agents
  4.3 Beta-adrenergic blocking agents
  4.4 Calcium channel blockers
  4.5 Short & Long - acting Nitroglycerines
  4.6 Angiotensin-converting enzyme inhibitors
  4.7 Anti-ischemic agents
  4.8 Pipeline Analysis
  4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
  4.8.1.1 Dantonic/T
  4.8.1.2 RANCAD
  4.8.1.3 Cilostazol
  4.8.1.4 Bococizumab
  4.8.1.5 Ticagrelor
  4.8.1.6 Auto-CD34+ cells
  4.8.1.7 Alirocumab
  4.8.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Angina Pectoris Treatment Market, By Geography
  5.1 Preface
  5.2 North America
  5.2.1 U.S
  5.2.2 Canada
  5.3 Europe
  5.3.1 U.K
  5.3.2 Germany
  5.3.3 Rest of Europe
  5.4 Asia Pacific
  5.4.1 China
  5.4.2 Japan
  5.4.3 Rest of Asia Pacific
  5.5 Rest of the World (RoW)
  5.5.1 Latin America
  5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Abbott Laboratories Inc.
   6.1.1 Business Description
   6.1.2 Financial Health and Budget Allocation
   6.1.3 Product Portfolio
   6.1.4 News Coverage
6.2 Astra Zeneca plc
   6.2.1 Business Description
   6.2.2 Financial Health and Budget Allocation
   6.2.3 Product Portfolio
   6.2.4 News Coverage
6.3 Bayer AG
   6.3.1 Business Description
   6.3.2 Financial Health and Budget Allocation
   6.3.3 Product Portfolio
   6.3.4 News Coverage
6.4 Bristol-Myers Squibb Company
   6.4.1 Business Description
   6.4.2 Financial Health and Budget Allocation
   6.4.3 Product Portfolio
   6.4.4 News Coverage
6.5 F. Hoffmann-La Roche Ltd.
   6.5.1 Business Description
   6.5.2 Financial Health and Budget Allocation
   6.5.3 Product Portfolio
   6.5.4 News Coverage
6.6 Forest Laboratories Inc.
   6.6.1 Business Description
   6.6.2 Financial Health and Budget Allocation
   6.6.3 Product portfolio
   6.6.4 News Coverage
6.7 Gilead Sciences, Inc.
   6.7.1 Business Description
   6.7.2 Financial Health and Budget Allocation
   6.7.3 Product Portfolio
   6.7.4 News Coverage
6.8 GlaxoSmithKline plc
   6.8.1 Business Description
   6.8.2 Financial Health and Budget Allocation
   6.8.3 Product Portfolio
   6.8.4 News Coverage
6.9 Novartis AG
   6.9.1 Business Description
   6.9.2 Financial Health and Budget Allocation
   6.9.3 Product Portfolio
   6.9.4 News Coverage
6.10 Pfizer Inc.
   6.10.1 Business Description
   6.10.2 Financial Health and Budget Allocation
   6.10.3 Product Portfolio
   6.10.4 News Coverage
6.11 Sanofi SA
   6.11.1 Business Description
   6.11.2 Financial Health and Budget Allocation
   6.11.3 Product Portfolio
   6.11.4 News Coverage

List of Figures:
- Figure 1 Global Angina Pectoris Treatment Market, by Drug Class, 2015 (USD Mn)
- Figure 2 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2015 & 2022 (USD Mn)
- Figure 3 Attractive Investment Proposition, Global Angina Pectoris Treatment Market
- Figure 4 Market Share Analysis: Global Angina Pectoris Treatment Market, 2015 (Value %)
- Figure 5 Global Antiplatelet agents Market for Angina Pectoris Treatment, 2013 - 2022 (USD Mn)
- Figure 6 Global Beta-adrenergic Blocking Agents Market for Angina Pectoris Treatment, 20137- 2022 (USD Mn)
Figure 7 Global Calcium Channel Blockers Market for Angina Pectoris Treatment, 2013 -2022 (USD Mn)
Figure 8 Global Short & Long - acting Nitroglycerines Market for Angina Pectoris Treatment, 2013 - 2022 (USD Mn)
Figure 9 Global Angiotensin-Converting Enzyme Inhibitors Market for Angina Pectoris Treatment, 2013 - 2022 (USD Mn)
Figure 10 Global Anti-ischemic agents Market for Angina Pectoris Treatment, 2013 - 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global Dantonic/T89 Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global RANCAD Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Cilostazol Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 14 Pipeline Analysis: Global Bococizumab Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 15 Pipeline Analysis: Global Ticagrelor Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 16 Pipeline Analysis: Global Auto-CD34+ cells Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 17 Pipeline Analysis: Global Alirocumab Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
Figure 18 Global U.S. Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 19 Global Canada Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 20 Global U.K Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 21 Global Germany Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 22 Global Rest of Europe Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 23 Global China Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 24 Global Japan Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 25 Global Rest of Asia Pacific Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 26 Global Latin America Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 27 Global Middle East and Africa Angina Pectoris Treatment Market Revenue, 2013 - 2022 (USD Mn)

List of Tables:
Table 1 Global Angina Pectoris Treatment Market Revenue, by Drug Class, 2013 - 2022 (USD Mn)
Table 2 Global Angina Pectoris Treatment Market Revenue, by Geography, 2013 - 2022 (USD Mn)
Table 3 North America Angina Pectoris Treatment Market Revenue, by Country, 2013 - 2022 (USD Mn)
Table 4 Europe Angina Pectoris Treatment Market Revenue, by Country, 2013 - 2022 (USD Mn)
Table 5 Asia - Pacific Angina Pectoris Treatment Market Revenue, by Country, 2013 - 2022 (USD Mn)
Table 8 Rest of the World Angina Pectoris Treatment Market Revenue, by Region, 2013 - 2022 (USD Mn)

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/3719684/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Angina Pectoris Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2012 To 2022
Web Address: http://www.researchandmarkets.com/reports/3719684/
Office Code: SCBRPAIV

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single User</td>
<td></td>
<td>USD 4100</td>
</tr>
<tr>
<td>Site License</td>
<td></td>
<td>USD 6200</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
<td>USD 8000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World